PCM
NVCR icon

Palisade Capital Management’s NovoCure NVCR Stock Holding History

Palisade Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,000
Closed -$225K – 430
2021
Q4 		$225K Buy
3,000
+200
+7% +$20.1K ﹤0.01% 414
2021
Q3 		$325K Buy
+2,800
New +$423K 0.01% 381

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Palisade Capital Management's NVCR Position: Q1 2022 in Review

Palisade Capital Management sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 3,000 shares — an estimated $225K sold.

Palisade Capital Management first reported a position in NVCR in Q3 2021 and held it in 2 quarters. The position peaked at $325K in Q3 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • Palisade Capital Management reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
  • Palisade Capital Management sold 3,000 NovoCure shares in Q1 2022, an estimated $225K.
  • Palisade Capital Management first reported a position in NovoCure in Q3 2021 and held it in 2 quarters.
  • Palisade Capital Management's NovoCure position peaked at $325K in Q3 2021.
  • 308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Palisade Capital Management's 13F filing for Q1 2022, filed 9 May 2022.